The Silent Echo: The aftermath of infections

Lecture / Panel
For NYU Community



Prem Premsrirut

President and CEO, Mirimus
Mirimus Inc.


Mirimus is a New York biotech company that propels scientific research in several areas, including oncology research using its cutting-edge RNA interference and genetic engineering technologies. When struck by COVID-19, Mirimus quickly launched a fast, low cost and scalable testing solution to serve its community and embarked on building novel diagnostic strategies to enable more rapid, point-of-care testing. We will share with you our journey, from bench-to-bedside, highlighting novel discoveries made and their path toward new therapeutic strategies.


Dr. Premsrirut is a co-founder and CEO of Mirimus, Inc., a company at the forefront of developing advanced RNA interference therapeutics in the form of artificial microRNAs (amiRNAs) used for precise gene modulation to treat human disease. By combining CRISPR gene editing and RNAi technologies, Mirimus has created hundreds of powerful disease models employed to propel the evaluation of novel therapeutic strategies, including the use of amiRNAs. Notably, at the start of the COVID-19 pandemic, Dr. Premsrirut led her team in a call to action to address the lack of efficient testing methods that would be required to reopen our schools and economy and was named a winner in the XPRIZE Rapid COVID-19 Testing Competition for Mirimus’ innovative SalivaClear strategy.  She and the team are leveraging the experience gained during the pandemic to develop diagnostic immunoassays and evaluate therapeutic targets to address long-COVID and other autoimmune diseases. Dr. Premsrirut earned a B.A. in Molecular and Cell Biology and Biochemistry from UC Berkeley and joint M.D./Ph.D. from SUNY Stony Brook School of Medicine and Cold Spring Harbor Laboratory.